Markers in the Diagnosis of TIA
MIND-TIA
1 other identifier
observational
350
1 country
1
Brief Summary
MIND-TIA is primarily an observational diagnostic study that aims to evaluate the role of novel biomarkers in the diagnosis of Transient Ischemic Attack (TIA)in primary care. Rapid and adequate diagnosis of TIA is of great importance to enable a rapid start of treatment, and thereby decrease the risk of subsequent ischemic stroke.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2013
CompletedFirst Submitted
Initial submission to the registry
September 26, 2013
CompletedFirst Posted
Study publicly available on registry
October 1, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2016
CompletedJune 15, 2015
June 1, 2015
2.5 years
September 26, 2013
June 12, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
'Definite' Diagnosis of TIA
Determined by expert panel consisting of 3 neurologists
After 6 months of follow-up
Secondary Outcomes (2)
Ischemic stroke and other cardiovascular events
During 6 months of follow-up
Time delay to GP consultation and start of treatment
1 day of home visit
Study Arms (1)
Patients suspected of TIA by the GP
Eligibility Criteria
350 patients suspected of TIA by the GP
You may qualify if:
- Being adult (18 years and older)
- Presenting to the GP with a new episode of symptoms suspected of TIA and the GP considering further investigations to confirm or exclude TIA at the TIA outpatient clinic.
- A blood sample can be collected within 72 hours after onset of symptoms.
You may not qualify if:
- The patient still has active symptoms or signs suspected of an ongoing ischemic stroke and immediate referral to the neurologist seems indicated.
- Valid history taking is impossible because of severe cognitive impairment or insufficient knowledge of the Dutch language.
- Patient with a life expectancy of \< 6 months.
- Patient is not willing or able to give written informed consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UMC Utrechtlead
- Saltro, diagnostic center for primary care.collaborator
Study Sites (1)
Julius Center UMC Utrecht
Utrecht, Utrecht, 3508 GA, Netherlands
Related Publications (2)
Dolmans LS, Rutten F, Bartelink MEL, van Dijk EJ, Nederkoorn PJ, Kappelle J, Hoes AW; MIND-TIA study group. Serum biomarkers in patients suspected of transient ischaemic attack in primary care: a diagnostic accuracy study. BMJ Open. 2019 Oct 17;9(10):e031774. doi: 10.1136/bmjopen-2019-031774.
PMID: 31628130DERIVEDDolmans LS, Rutten FH, El Bartelink ML, Seppenwoolde G, van Delft S, Kappelle LJ, Hoes AW. Serum biomarkers for the early diagnosis of TIA: The MIND-TIA study protocol. BMC Neurol. 2015 Jul 28;15:119. doi: 10.1186/s12883-015-0388-z.
PMID: 26215720DERIVED
Related Links
Biospecimen
Serum, RNA and DNA material.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- MD, PhD
Study Record Dates
First Submitted
September 26, 2013
First Posted
October 1, 2013
Study Start
September 1, 2013
Primary Completion
March 1, 2016
Last Updated
June 15, 2015
Record last verified: 2015-06